Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 405

1.

The microbiome in lung cancer tissue and recurrence-free survival.

Peters BA, Hayes RB, Goparaju C, Reid C, Pass HI, Ahn J.

Cancer Epidemiol Biomarkers Prev. 2019 Feb 7. pii: cebp.0966.2018. doi: 10.1158/1055-9965.EPI-18-0966. [Epub ahead of print]

PMID:
30733306
2.

Expert Consensus Document on Pulmonary Metastasectomy.

Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, Firestone S, Johnstone CA, Lanuti M, Litle VR, Kesler KA, Mitchell JD, Pass HI, Ross HJ, Varghese TK.

Ann Thorac Surg. 2019 Feb;107(2):631-649. doi: 10.1016/j.athoracsur.2018.10.028. Epub 2018 Nov 23. No abstract available.

PMID:
30476477
3.

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).

Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ.

Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.

PMID:
30442588
4.

A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.

Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, Takinishi Y, Yamamoto R, Minaai M, Hashimoto-Tamaoki T, Ohmuraya M, Goto K, Goparaju C, Sarin KY, Tanji M, Bononi A, Napolitano A, Gaudino G, Hesdorffer M, Yang H, Carbone M.

J Clin Oncol. 2018 Oct 30:JCO2018790352. doi: 10.1200/JCO.2018.79.0352. [Epub ahead of print]

PMID:
30376426
5.

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G.

Cell Death Differ. 2018 Nov;25(11):1885-1904. doi: 10.1038/s41418-018-0213-5. Epub 2018 Oct 15.

PMID:
30323273
6.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
7.

PACIFIC: Time for a surgical IIIA uprising.

Pass HI.

J Thorac Cardiovasc Surg. 2018 Sep;156(3):1249-1254. doi: 10.1016/j.jtcvs.2018.05.059. Epub 2018 Jun 4. No abstract available.

PMID:
30017445
8.

Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.

Ooki A, Dinalankara W, Marchionni L, Tsay JJ, Goparaju C, Maleki Z, Rom WN, Pass HI, Hoque MO.

Oncogene. 2018 Nov;37(45):5967-5981. doi: 10.1038/s41388-018-0373-2. Epub 2018 Jul 6.

9.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
10.

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H.

JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251.

PMID:
29852037
11.

Sphenopalatine Ganglion Block to Treat Shoulder Tip Pain After Thoracic Surgery: Report of 2 Cases.

Grant GJ, Echevarria GC, Lax J, Pass HI, Oshinsky ML.

A A Pract. 2018 Aug 15;11(4):90-92. doi: 10.1213/XAA.0000000000000746.

PMID:
29634542
12.

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.

Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, Goparaju C, Yang H, Hammond E, Zhang G, Li JP, Ilan N, Nagler A, Pass HI, Vlodavsky I.

J Natl Cancer Inst. 2018 Oct 1;110(10):1102-1114. doi: 10.1093/jnci/djy032.

PMID:
29579286
13.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

PMID:
29524617
14.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

15.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26. Review.

PMID:
29480761
16.

Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.

17.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

18.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

19.

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M.

Oncogene. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8. Epub 2018 Jan 9.

PMID:
29311642
20.

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR.

J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.

21.

Prognosis and "granularity": Building on staging foundations?

Pass HI.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):354-355. doi: 10.1016/j.jtcvs.2017.10.032. Epub 2017 Oct 20. No abstract available.

PMID:
29100584
22.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

23.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

24.

Lepidic Predominant Pulmonary Lesions (LPL): CT-based Distinction From More Invasive Adenocarcinomas Using 3D Volumetric Density and First-order CT Texture Analysis.

Alpert JB, Rusinek H, Ko JP, Dane B, Pass HI, Crawford BK, Rapkiewicz A, Naidich DP.

Acad Radiol. 2017 Dec;24(12):1604-1611. doi: 10.1016/j.acra.2017.07.008. Epub 2017 Aug 24.

PMID:
28844845
25.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

26.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

27.

Diagnosis and prognosis-review of biomarkers for mesothelioma.

Sun HH, Vaynblat A, Pass HI.

Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Review.

28.

Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.

Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ.

Clin Proteomics. 2017 Jul 5;14:25. doi: 10.1186/s12014-017-9158-9. eCollection 2017.

29.

Quality Initiatives: Baby Steps in the Right Direction.

Pass HI.

Semin Thorac Cardiovasc Surg. 2017 Spring;29(1):102-103. doi: 10.1053/j.semtcvs.2017.03.005. Epub 2017 Mar 31.

PMID:
28683984
30.

Germline BAP1 mutations induce a Warburg effect.

Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M.

Cell Death Differ. 2017 Oct;24(10):1694-1704. doi: 10.1038/cdd.2017.95. Epub 2017 Jun 30.

31.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

32.

Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize.

Pass HI.

J Thorac Oncol. 2017 Jun;12(6):919-921. doi: 10.1016/j.jtho.2017.04.013. No abstract available.

33.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.

PMID:
28437162
34.

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.

Becker DJ, Levy BP, Gold HT, Sherman SE, Makarov DV, Schreiber D, Wisnivesky JP, Pass HI.

Am J Clin Oncol. 2018 Aug;41(8):820-825. doi: 10.1097/COC.0000000000000379.

PMID:
28301349
35.

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H.

J Transl Med. 2017 Mar 15;15(1):58. doi: 10.1186/s12967-017-1158-z.

36.

Introduction: Great Institutions in Cardiothoracic Surgery, Second Edition.

Rosengart TK, Austin EH, Pass HI, Weisel RD.

Semin Thorac Cardiovasc Surg. 2016 Autumn;28(3):609-610. doi: 10.1053/S1043-0679(17)30038-2. No abstract available.

PMID:
28285664
37.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H.

Oncotarget. 2017 Apr 4;8(14):22649-22661. doi: 10.18632/oncotarget.15152.

38.

Improving the Accuracy of Mesothelioma Diagnosis in China.

Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W.

J Thorac Oncol. 2017 Apr;12(4):714-723. doi: 10.1016/j.jtho.2016.12.006. Epub 2016 Dec 19.

39.

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.

Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M.

JAMA Oncol. 2017 Apr 1;3(4):562-564. doi: 10.1001/jamaoncol.2016.5487. No abstract available.

40.

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.

Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437. Epub 2016 Nov 9.

41.

Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity.

Larson D, Powers A, Ambrosi JP, Tanji M, Napolitano A, Flores EG, Baumann F, Pellegrini L, Jennings CJ, Buck BJ, McLaurin BT, Merkler D, Robinson C, Morris P, Dogan M, Dogan AU, Pass HI, Pastorino S, Carbone M, Yang H.

J Toxicol Environ Health B Crit Rev. 2016;19(5-6):213-230.

42.

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. Epub 2016 Sep 26.

43.

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.

44.

A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.

Rusch VW, Gill R, Mitchell A, Naidich D, Rice DC, Pass HI, Kindler HL, De Perrot M, Friedberg J; Malignant Mesothelioma Volumetric CT Study Group.

Ann Thorac Surg. 2016 Oct;102(4):1059-66. doi: 10.1016/j.athoracsur.2016.06.069. Epub 2016 Sep 2.

45.

Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.

Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G, Cioce M.

Oncotarget. 2016 Aug 30;7(35):56408-56421. doi: 10.18632/oncotarget.10895.

46.

Consensus Report of the 2015 Weinman International Conference on Mesothelioma.

Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S.

J Thorac Oncol. 2016 Aug;11(8):1246-1262. doi: 10.1016/j.jtho.2016.04.028.

47.

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.

Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S.

Oncotarget. 2016 Sep 13;7(37):59314-59321. doi: 10.18632/oncotarget.10653.

48.

Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection.

Lee LJ, Yang Z, Rahman M, Ma J, Kwak KJ, McElroy J, Shilo K, Goparaju C, Yu L, Rom W, Kim TK, Wu X, He Y, Wang K, Pass HI, Nana-Sinkam SP.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1431-3. doi: 10.1164/rccm.201511-2129LE. No abstract available.

49.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

50.

Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer.

Pekarsky Y, Balatti V, Palamarchuk A, Rizzotto L, Veneziano D, Nigita G, Rassenti LZ, Pass HI, Kipps TJ, Liu CG, Croce CM.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5071-6. doi: 10.1073/pnas.1604266113. Epub 2016 Apr 11.

Supplemental Content

Support Center